By establishing the MiniPDX model, Xu et al. [42] found that the combined application of AKT inhibitors and PARP inhibitors might be a feasible method for clinical trials in patients with recurrent ovarian cancer. This evidence concerns the gene AKT1 and ovarian cancer.